Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse

Asuka Nakarai, Sakiko Hiraoka, Sakuma Takahashi, Tomoki Inaba, Reiji Higashi, Motowo Mizuno, Shiho Takashima, Toshihiro Inokuchi, Yuusaku Sugihara, Masahiro Takahara, Keita Harada, Jun Kato, Hiroyuki Okada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. Results: A total of 113 patients were enrolled, and 48 [42%] relapsed. Fcal = 75 μg/g and FIT = 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95% confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95% CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95% CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95% CI, 2.57- 11.76; p < 0.0001, compared with both negative]. Conclusions: Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.

Original languageEnglish
Pages (from-to)71-76
Number of pages6
JournalJournal of Crohn's and Colitis
Volume12
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Leukocyte L1 Antigen Complex
Ulcerative Colitis
Recurrence
Confidence Intervals
Colonoscopy
ROC Curve

Keywords

  • Faecal calprotectin
  • Quantitative faecal immunochemical test
  • Relapse
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. / Nakarai, Asuka; Hiraoka, Sakiko; Takahashi, Sakuma; Inaba, Tomoki; Higashi, Reiji; Mizuno, Motowo; Takashima, Shiho; Inokuchi, Toshihiro; Sugihara, Yuusaku; Takahara, Masahiro; Harada, Keita; Kato, Jun; Okada, Hiroyuki.

In: Journal of Crohn's and Colitis, Vol. 12, No. 1, 01.01.2018, p. 71-76.

Research output: Contribution to journalArticle

Nakarai, Asuka ; Hiraoka, Sakiko ; Takahashi, Sakuma ; Inaba, Tomoki ; Higashi, Reiji ; Mizuno, Motowo ; Takashima, Shiho ; Inokuchi, Toshihiro ; Sugihara, Yuusaku ; Takahara, Masahiro ; Harada, Keita ; Kato, Jun ; Okada, Hiroyuki. / Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse. In: Journal of Crohn's and Colitis. 2018 ; Vol. 12, No. 1. pp. 71-76.
@article{5b7ee00ff5954318b345c93722f2b308,
title = "Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse",
abstract = "Background: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. Results: A total of 113 patients were enrolled, and 48 [42{\%}] relapsed. Fcal = 75 μg/g and FIT = 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95{\%} confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95{\%} CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95{\%} CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95{\%} CI, 2.57- 11.76; p < 0.0001, compared with both negative]. Conclusions: Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.",
keywords = "Faecal calprotectin, Quantitative faecal immunochemical test, Relapse, Ulcerative colitis",
author = "Asuka Nakarai and Sakiko Hiraoka and Sakuma Takahashi and Tomoki Inaba and Reiji Higashi and Motowo Mizuno and Shiho Takashima and Toshihiro Inokuchi and Yuusaku Sugihara and Masahiro Takahara and Keita Harada and Jun Kato and Hiroyuki Okada",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/ecco-jcc/jjx118",
language = "English",
volume = "12",
pages = "71--76",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Simultaneous measurements of faecal calprotectin and the faecal immunochemical test in quiescent ulcerative colitis patients can stratify risk of relapse

AU - Nakarai, Asuka

AU - Hiraoka, Sakiko

AU - Takahashi, Sakuma

AU - Inaba, Tomoki

AU - Higashi, Reiji

AU - Mizuno, Motowo

AU - Takashima, Shiho

AU - Inokuchi, Toshihiro

AU - Sugihara, Yuusaku

AU - Takahara, Masahiro

AU - Harada, Keita

AU - Kato, Jun

AU - Okada, Hiroyuki

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. Results: A total of 113 patients were enrolled, and 48 [42%] relapsed. Fcal = 75 μg/g and FIT = 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95% confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95% CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95% CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95% CI, 2.57- 11.76; p < 0.0001, compared with both negative]. Conclusions: Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.

AB - Background: Both faecal calprotectin [Fcal] and the faecal immunochemical test [FIT] are useful to predict clinical relapse of ulcerative colitis [UC]. However, the difference between Fcal and FIT in ability to predict relapse has scarcely been reported. Whether the combined use of these two faecal markers increases the predictability is also unknown. Methods: UC patients in clinical remission who underwent colonoscopy were enrolled prospectively, and the Fcal and FIT values were examined at enrolment. Their clinical course was observed for 2 years or until relapse. The correlation between the incidence of relapse and the values of the two markers was examined. Results: A total of 113 patients were enrolled, and 48 [42%] relapsed. Fcal = 75 μg/g and FIT = 110 ng/mL were defined as Fcal-positive and FIT-positive, respectively, according to the receiver operating characteristic curves. Both Fcal-positive and FIT-positive statuses were independent predictive factors of clinical relapse (hazard ratio [HR] 2.29; 95% confidence interval [CI], 1.23-4.49; p = 0.0086, and HR 2.91; 95% CI, 1.49-5.50; p = 0.0022, respectively). Categorisation of patients into three groups according to the faecal marker status [FIT-positive, FIT-negative and Fcal-positive, and both negative] can efficiently stratify the risk of relapse with graded increases in risk [FIT-negative and Fcal-positive: HR 2.05; 95% CI, 1.02-4.43; p = 0.0045, and FIT-positive: HR 5.43; 95% CI, 2.57- 11.76; p < 0.0001, compared with both negative]. Conclusions: Fcal vs FIT showed distinct properties regarding the prediction of relapse in UC. A risk assessment using both faecal markers could increase the predictability for relapse.

KW - Faecal calprotectin

KW - Quantitative faecal immunochemical test

KW - Relapse

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85040547031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040547031&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjx118

DO - 10.1093/ecco-jcc/jjx118

M3 - Article

C2 - 28961792

AN - SCOPUS:85040547031

VL - 12

SP - 71

EP - 76

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 1

ER -